Form 4: Nuvation Bio Director Robert Mashal Granted Significant Stock Options

Nuvation Bio Inc. Director and 10% owner Robert Mashal was granted 292,983 stock options with an exercise price of $2.03, vesting on the earlier of May 21, 2025, or the next shareholder annual meeting.

Summary

• Robert Mashal, a Director and 10% owner of Nuvation Bio Inc. (NUVB), was granted 292,983 stock options.
• The options have an exercise price of $2.03 per share.
• The grant date for these options was May 21, 2025.
• The options are for Class A Common Stock.
• 100% of the shares subject to the option will vest on the earlier of the one-year anniversary of the grant date (May 21, 2025) or the next shareholder annual meeting, contingent on Mr. Mashal's continuous service.
• The options expire on May 20, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive signal of alignment between management/board and shareholder interests, as it incentivizes long-term stock performance. It's a routine compensation event, so not highly impactful on its own, but generally viewed favorably.

Positives

• The grant of stock options to Director Robert Mashal aligns his interests with long-term shareholder value, as the options gain value only if the stock price increases above the exercise price of $2.03.
• The options have a long expiration date of May 20, 2035, providing a significant window for potential value realization.

Negatives

• The exercise price of $2.03 means the options only become 'in-the-money' if Nuvation Bio's stock price rises above this level, representing a potential dilution if exercised and the stock price is higher.

Risks

• The vesting of the options is subject to the Reporting Person's continuous service through the applicable vesting date, meaning the options could be forfeited if service is terminated prior to vesting.

Future Outlook

The document indicates a future vesting event for the granted stock options, contingent on the director's continuous service, which could occur on the one-year anniversary of the grant date (May 21, 2025) or the next shareholder annual meeting.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and pharmaceutical industries where equity grants, such as stock options, are a common component of executive and director compensation packages. These grants are designed to incentivize long-term performance and align the interests of key personnel with those of shareholders, a critical aspect in R&D-intensive sectors like biotech where long development cycles are common.

Related Party Transactions

• The grant of stock options to Robert Mashal, a Director and 10% owner, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• **Shareholders**: The grant of stock options aims to align the director's interests with shareholders by incentivizing an increase in the company's stock price. However, future exercise of these options could lead to dilution.
• **Employees**: While not directly impacting general employees, such grants to leadership can signal confidence in the company's future, potentially boosting morale.

Next Steps

• The stock options granted to Robert Mashal are scheduled to vest on the earlier of May 21, 2025, or the next shareholder annual meeting, subject to his continuous service.

Key Dates

Keywords

Nuvation Bio Inc., NUVB, SEC Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Grant, Robert Mashal, Biotechnology, Pharmaceuticals